Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9924632Aexternal-prioritypatent/GB2342959B/en
Application filed by PfizerfiledCriticalPfizer
Publication of ECSP003703ApublicationCriticalpatent/ECSP003703A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Los compuestos de la fórmula (I) en la que R1, R2, R4 y R13 son como se han definido, una sal o polimorfo farmacéutica o veterinariamente aceptable de los mismos, o un solvato o profármaco farmacéutica o veterinariamente aceptable de los mismos, son inhibidores potentes y selectivos de la guanosina 3´, 5´-monofosfato cíclico fosfodiesterasa de tipo 5 (GPMc PDE5) y tienen utilidad en el tratamiento de, entre otras afecciones, la disfunción eréctil masculina (MED) y la disfunción sexual femenina (FSD).The compounds of the formula (I) in which R1, R2, R4 and R13 are as defined, a pharmaceutically or veterinarily acceptable salt or polymorph thereof, or a pharmaceutically or veterinarily acceptable solvate or prodrug thereof, are potent and selective guanosine 3´, 5´-cyclic phosphodiesterase type 5 inhibitors (GPMc PDE5) and have utility in the treatment of, among other conditions, male erectile dysfunction (MED) and female sexual dysfunction (FSD) .
ECSP0037031999-10-182000-10-10
PHARMACEUTICALLY ACTIVE COMPOUNDS
ECSP003703A
(en)
PIRAZOLO COMPOUNDS [4,3-] PIRIMIDIN-7-ONAS, PHARMACEUTICAL COMPOSITION, VETERINARY FORMULATION, USE IN THE MANUFACTURE OF MEDICINAL PRODUCT, PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS, INTERMEDIARY COMPOUNDS AND THEIR PREPARATION
Pyrazolopyrimidinones which inhibit type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterase (cGMP PDE5) for the treatment of sexual dysfunction